Hamburg, Germany
Topas Therapeutics GmbH is a clinical-stage biotechnology innovator, founded in 2016 and headquartered in Germany. The company is pioneering advances in immune tolerance through its unique antigen-specific and targeted nanoparticle technology. Utilizing the liver's natural capacity for tolerance, their proprietary Topas Particles Conjugates effectively engage liver sinusoidal endothelial cells to induce T cell tolerance, offering a promising approach to treating autoimmune diseases.
With an adaptable technology platform for various disease-relevant antigens, Topas Therapeutics is building a robust clinical pipeline aimed at establishing systemic tolerance. This potential is underscored by its successful €18.00M Series B investment in July 2021, backed by notable investors including GIMV, BioMed Partners, Boehringer Ingelheim, EMBL Ventures, Epidarex Capital, Evotec, and Vesalius Biocapital. The company is strategically positioned to provide meaningful therapeutic benefits to patients with autoimmune diseases.
